Mazdutide Shows Promise in Treating Metabolic Disorders, Lowers Uric Acid
San Francisco,CA – Mazdutide,a dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonist,is demonstrating potential in alleviating hyperuricemia by modulating hepatic energy and lipid metabolism,according to research presented at the American Diabetes Association (ADA) 85th Scientific Sessions. The studies, highlighted by Innovent Biologics, suggest that mazdutide could offer a novel therapeutic approach for metabolic disorders.
Mazdutide’s Impact on uric acid Levels and metabolic Function
Research indicates that mazdutide substantially reduces serum uric acid levels in hyperuricemic rats by enhancing fatty acid oxidation and regulating cellular energy metabolism within hepatocytes. This process suppresses the expression of genes associated with glucose and purine metabolism in the liver,leading to a reduction in the generation and utilization of purine precursors. A study published in the journal, *Metabolism*, also supports the role of GLP-1 receptor agonists in improving metabolic function [1].
Did You Know? Uric acid is a waste product created when your body breaks down purines, substances found naturally in your body and in foods such as steak, organ meats, and seafood [2].
Key Findings from the Research:
- Mazdutide increases the expression of GCGR in hepatocytes,promoting fatty acid oxidation.
- Expression of key genes involved in fatty acid oxidation, such as Cpt1a, Fabp1, Apoa1, Acox1, and Acaa1a, is significantly increased following mazdutide treatment.
- Genes associated with fatty acid synthesis,such as Acaca and Fasn,show a meaningful reduction in expression.
- expression of genes related to glucose metabolism and purine metabolism, including Pklr, G6pc1, Glul, Gckr, Gk, Nt5e, and Ppat, also experience significant decreases.
Compared to semaglutide,another GLP-1 receptor agonist,mazdutide offers more substantial benefits in lowering uric acid levels,according to the study.
Innovent’s Perspective on Mazdutide’s Potential
Dr. Lei Qian from Innovent Biologics emphasized the meaning of these findings, stating, “We are delighted to see mazdutide’s mechanism exploration studies featured extensively at the ADA conference.The growing body of scientific evidence will further validate mazdutide’s differentiated profile as a next-generation GCG/GLP-1 dual receptor agonist, particularly in liver fat and serum urine reduction.”
Innovent is also developing IBI3030 (PCSK9-GGG), a novel therapy with a unique mechanism of action aimed at delivering comprehensive therapeutic benefits for patients with cardiovascular and metabolic diseases.
Mazdutide (IBI362): A Dual Agonist
Mazdutide, also known as IBI362, is a GLP-1R and GCGR dual agonist developed under an exclusive license agreement between Innovent and Eli Lilly and Company in China. as a mammalian oxyntomodulin (OXM) analogue, mazdutide activates both the glucagon receptor and GLP-1 receptor, potentially offering benefits beyond those of GLP-1 receptor agonists alone. These benefits include promoting insulin secretion, lowering blood glucose, reducing body weight, increasing energy expenditure, and improving hepatic fat metabolism.
Pro Tip: Dual agonists like Mazdutide may offer a more comprehensive approach to managing metabolic disorders by targeting multiple pathways together.
Currently, mazdutide has two New Drug Applications (NDAs) accepted for review by China’s National Medical Products Governance (NMPA) for long-term weight management in adults with obesity or overweight and glycemic control in adults with type 2 diabetes (T2D).
Ongoing Clinical Trials
Mazdutide is currently being evaluated in seven Phase 3 clinical studies, including trials focused on overweight or obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), obstructive sleep apnea (OSA), and type 2 diabetes (T2D).Several new clinical studies are also planned, including trials in adolescents with obesity, metabolic dysfunction-associated steatohepatitis (MASH), and heart failure with preserved ejection fraction (HFpEF).
| Trial Name | target Population | Status |
|---|---|---|
| GLORY-1 | Chinese participants with overweight or obesity | Met Primary Endpoints |
| GLORY-2 | Chinese participants with moderate-to-severe obesity | Ongoing |
| GLORY-3 | Chinese participants with overweight/obesity and MAFLD | Ongoing |
| GLORY-OSA | Chinese participants with OSA and obesity | Ongoing |
| DREAMS-1 | Treatment-naïve Chinese participants with T2D | Met Primary Endpoints |
| DREAMS-2 | Chinese T2D participants with inadequate glycemic control | Met Primary Endpoints |
| DREAMS-3 | Chinese participants with T2D and obesity | Ongoing |
With the promising results from ongoing trials,what impact could Mazdutide have on the treatment of metabolic disorders in the future? how might dual-agonist therapies change the landscape of diabetes and obesity management?
The Growing Need for Metabolic Disorder Treatments
The prevalence of metabolic disorders,including obesity,type 2 diabetes,and hyperuricemia,is increasing globally. According to the World Health Organization (WHO), over 650 million adults worldwide are obese [3].These conditions frequently enough coexist and contribute to significant health complications, such as cardiovascular disease, liver disease, and kidney disease. The development of novel therapies like mazdutide is crucial to addressing this growing health crisis.
The global market for diabetes treatment is projected to reach $141.7 billion by 2028,growing at a CAGR of 6.8% from 2021 [4]. This highlights the substantial investment and ongoing research efforts in this field.
Frequently Asked Questions About Mazdutide
Disclaimer: This article provides data about ongoing research and potential therapeutic options. It is not intended to provide medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of medical conditions.
Share your thoughts: How do you see dual-agonist therapies impacting the future of metabolic disease treatment? Leave a comment below!
